Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia

Página do item simplificado Estatísticas
dc.contributor.authorSoares, Bruno Lobão
dc.contributor.authorOliveira, João Paulo Maia de
dc.contributor.authorMachado-de-Sousa, João Paulo
dc.contributor.authorBaker, Glen B.
dc.contributor.authorDursun, Serdar
dc.contributor.authorHallak, Jaime E. C.
dc.date.accessioned2018-06-16T15:43:29Z
dc.date.available2018-06-16T15:43:29Z
dc.date.issued2011-09
dc.description.resumoSchizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors.pt_BR
dc.identifier.citationSOARES, Bruno Lobão et al.Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Revista Brasileira de Psiquiatria, v. 33, p. 223-224, 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000300003&lng=en&tlng=en>. Acesso em: 23 mar. 2018.pt_BR
dc.identifier.doihttp://dx.doi.org/10.1590/S1516-44462011000300003
dc.identifier.issn1809-452X
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/25437
dc.languageengpt_BR
dc.publisherAssociação Brasileira de Psiquiatriapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSchizophreniapt_BR
dc.titleTargeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophreniapt_BR
dc.title.alternativeA via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofreniapt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
TargetingNMDAReceptor_Soares_2011.pdf
Tamanho:
362.34 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar

Coleções

CB - DBF - Artigos publicados em periódicos
Repositório Institucional - UFRN Campus Universitário Lagoa NovaCEP 59078-970 Caixa postal 1524 Natal/RN - BrasilUniversidade Federal do Rio Grande do Norte© Copyright 2025. Todos os direitos reservados.
Contato+55 (84) 3342-2260 - R232Setor de Repositórios Digitaisrepositorio@bczm.ufrn.br
DSpaceIBICT
OasisBR
LAReferencia
Customizado pela CAT - BCZM